MarketInOut Stock Screener Log In | Sign Up
 

Can-Fite Biopharma Ltd ADR

NYSE • Healthcare • Biotechnology • Quote as of 10/16/2026 16:00
Can-Fite Biopharma Ltd ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization5.91 mln
Float2.13 mln
Earnings Date04/01/2027

Piotroski F-Score

2 / 9
Weak

Relative Strength

4 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

Pre-Tax Margin

-2,362%
Severely loss-making

ROE

-196
Deeply negative

Altman Z-Score

-27.73
Deeply distressed

Business Description

Can-Fite BioPharma is an Israeli drug development company focused on creating oral treatments for cancer, liver disease, and erectile dysfunction. Its two most advanced medicines, Piclidenoson and Namodenoson, are being tested in late-stage clinical trials for conditions including psoriasis, liver cancer, and pancreatic cancer. The company also partners with other firms to expand the reach of its treatments and explore cannabis-based therapies for cancer and inflammatory conditions. Founded in 1994 and based in Ramat Gan, Israel, Can-Fite also offers a diagnostic blood test to help predict how patients may respond to its drugs.

Key Fundamentals

EPS-13.23
ROE-196
RPS0.28
ROIC-734
ROA-113
EBITDA, mln-9.61
EV / EBITDA0.07
EV / EBIT0.07
Revenue, mln0.41

Quote Details

Last 1.76
Change -0.09 (-4.86%)
Open 1.92
Volume 26,978
Turnover 47,481
Average Volume 33,292

Financial Ratios

Pre-Tax Profit Margin-2,362
Leverage Ratio1.66
Current Ratio3.60
Price / Book1.03
Price / Tangible Book1.03
Debt / Equity0.01
Price / Sales8.27

Financial Strength

Altman Z-Score-27.73
Piotroski F-Score 2 / 9
Short Ratio0.06
Short % of Float1.84

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -7.37% 11 / 100   
1 Month -21.43% 4 / 100   
2 Months -46.01% 2 / 100   
6 Months -42.11% 4 / 100   
1 Year -83.33% 1 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us